News
Video
Author(s):
Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.
Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC
FDA Approval Insights: Ponatinib in Ph+ ALL
Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation
Revisit Every OncLive On Air Episode From May 2024
Earlier Use of Acalabrutinib Associated With Improved Survival in CLL
CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL
Ponatinib Regimen Shows Long-term Efficacy in Acute Lymphoblastic Leukemia
Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma